Compass Therapeutics, Inc. cash flow to debt ratio of -499.98% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Compass Therapeutics, Inc.'s free cash flow has decreased 9.51% from $-44.90M last year to $-49.17M, signaling decreasing performance

Compass Therapeutics, Inc.'s debt to equity ratio is 0.06, which means that the company's assets are healthy financed, signaling financial stability.

Compass Therapeutics, Inc.'s debt has increased relative to shareholder equity from 0.05 last year to 0.06 today, signaling weakened financials

Compass Therapeutics, Inc. has a net cash position, so leverage is healthy.

Compass Therapeutics, Inc. earns at least as much interest as it pays. Interest obligations are fully covered.

Compass Therapeutics, Inc.'s profit margin has increased (-100.00%) in the last year from -5.81K% to 0.00%, signaling increasing performance

Compass Therapeutics, Inc.'s short-term assets of $209.82M exceed its short-term liabilities of $13.97M

Compass Therapeutics, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Compass Therapeutics, Inc.'s return on equity of -38.71%, is lower than 15.00%, indicating bad performance

Compass Therapeutics, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Compass Therapeutics, Inc. had positive net income in only 0 out of 5 years, indicating unstable earnings

Compass Therapeutics, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Compass Therapeutics, Inc. has negative free cash flow, indicating cash burn

Compass Therapeutics, Inc.'s yearly earnings has decreased 34.66% since last year from $-49.38M to $-66.49M, signaling decreasing performance

Compass Therapeutics, Inc.'s yearly revenue has decreased 100.00% since last year from $850.00K to $0.00, signaling decreasing performance

ROIC -46.15% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Compass Therapeutics, Inc. has insufficient revenue history to calculate 3-year revenue CAGR.

Compass Therapeutics, Inc. had revenue growth in 4 out of 5 years, indicating consistent revenue performance

Compass Therapeutics, Inc. had positive ROE in only 0 out of 5 years, indicating inconsistent returns on equity

Compass Therapeutics, Inc. has insufficient data to evaluate this check.

Compass Therapeutics, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Compass Therapeutics, Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Compass Therapeutics, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Compass Therapeutics, Inc. has insufficient data to evaluate this check.

Compass Therapeutics, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Compass Therapeutics, Inc. has a price-to-book ratio of 2.50x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

Compass Therapeutics, Inc. has a price-to-sales ratio of 999.00x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue